Development of molecular targeting therapy for head and neck cancer by targeting membrane type MMP and EBV antigen
靶向膜型MMP和EBV抗原开发头颈癌分子靶向治疗
基本信息
- 批准号:15390514
- 负责人:
- 金额:$ 6.98万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (B)
- 财政年份:2003
- 资助国家:日本
- 起止时间:2003 至 2005
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
1)Cytotoxic and cytostatic effect of Anti-MT1-MMP antibody 114F1 labeled with 131I was evaluated between HEK293 cell and MT1-MMP stable transfected-HEK293. Colony, formation assay showed there was no difference between these two cells, indicating that anti-MT1MMP with 131I did not have cytostatic effect. However, additional BB94, an inhibitor of MMP, enhanced the expression of cell surface MT1-MMP, and binding affinity of antibody to cell was enhanced 10 to 20% when 100ug of antibody was administrated.2)Affinity to MT1MMP was reevaluated among,114F,113-5B7 and AB815 using flow cytometry. It showed that AB815 had 5 to 10 fold binding affinity compared with either 114F or 113-5B7. These, results suggests that molecular targeting therapy against MT1-MMP would be improved by the use of higher affinity antibodies and MMP inhibitors.3)Epstein-Barr virus primary oncogene LMP1 locates on cell membrane. Establishment of antibody to LMP1 was first designed. However, ectodomain of LMP1 was revealed to have 6to 7 amino acids, which is insufficient to raise antibody.4)Then, the strategy was switched to look for the cell surface molecule induced by LMP1. Mucin1 was found to a specific molecule induced by LMP1 and effect, of antibody against-mucin1 should be examined in the successional experiment.
1)在HEK 293细胞和MT 1-MMP稳定转染的HEK 293之间评价131 I标记的抗MT 1-MMP抗体114 F1的细胞毒性和细胞抑制作用。集落形成实验显示两种细胞间无差异,表明抗MT 1 MMP与131 I联合作用不具有细胞抑制作用。而加入MMP抑制剂BB 94后,细胞表面MT 1-MMP的表达增强,当加入100 μ g抗体时,抗体与细胞的结合亲和力提高了10 ~ 20%。2)流式细胞术检测114 F、113- 5 B7和AB 815对MT 1-MMP的亲和力。结果表明,与114 F或113- 5 B7相比,AB 815具有5至10倍的结合亲和力。结论:3)EB病毒原癌基因LMP 1定位于细胞膜上。首先设计了抗LMP 1抗体的建立。但是,LMP 1的胞外结构域只有6 ~ 7个氨基酸,不足以产生抗体。4)随后,我们将策略转移到寻找LMP 1诱导的细胞表面分子上。Mucin 1是LMP 1诱导的特异性分子,其作用效果有待于后续实验的进一步研究。
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration
- DOI:10.1074/jbc.m306736200
- 发表时间:2003-10-17
- 期刊:
- 影响因子:4.8
- 作者:Endo, K;Takino, T;Sato, H
- 通讯作者:Sato, H
Metastasizing mixed tumour of the parotid gland presenting as multiple lung metastases.
腮腺转移性混合瘤表现为多发性肺转移。
- DOI:
- 发表时间:2004
- 期刊:
- 影响因子:0
- 作者:Tonchev AB;Yamashima T;Sawamoto K;Okano H.;Yoshizaki T et al.
- 通讯作者:Yoshizaki T et al.
Chapter 12,Epstein-Barr virus, invasion and metastasis "Epstein-Barr virus".
第12章,Epstein-Barr病毒,侵袭和转移“Epstein-Barr病毒”。
- DOI:
- 发表时间:2005
- 期刊:
- 影响因子:0
- 作者:Yoshizaki T.;et al.
- 通讯作者:et al.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YOSHIZAKI Tomokazu其他文献
YOSHIZAKI Tomokazu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YOSHIZAKI Tomokazu', 18)}}的其他基金
Tumor-targeted chemotherapy with the nanopolymer-based drug NC-6004 for oral squamous cell carcinoma
使用基于纳米聚合物的药物 NC-6004 治疗口腔鳞状细胞癌的肿瘤靶向化疗
- 批准号:
23659792 - 财政年份:2011
- 资助金额:
$ 6.98万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
The role of intrinsic immunity for EBV-mediated nasopharyngeal carcinogenesis
内在免疫在 EBV 介导的鼻咽癌发生中的作用
- 批准号:
23390396 - 财政年份:2011
- 资助金额:
$ 6.98万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Molecular mechanism of nasopharyngeal carcinoma oncogenesis by Epstein-Barr virus RNA EBERs
Epstein-Barr病毒RNA EBERs导致鼻咽癌发生的分子机制
- 批准号:
13671775 - 财政年份:2001
- 资助金额:
$ 6.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)